Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma-Reference-Cited by-同舟云学术

Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma

Published:2010-09 Issue:5 Volume:15 Page:654-660
ISSN:0949-2658
Container-title:Journal of Orthopaedic Science
language:en
Short-container-title:Journal of Orthopaedic Science

Author:

Sugiura Hideshi,Fujiwara Yasuhiro,Ando Masashi,Kawai Akira,Ogose Akira,Ozaki Toshifumi,Yokoyama Ryohei,Hiruma Toru,Ishii Takeshi,Morioka Hideo,Mugishima Hideo

Publisher

Elsevier BV

Subject

Orthopedics and Sports Medicine,Surgery

Link

http://www.springerlink.com/index/pdf/10.1007/s00776-010-1506-9

Reference30 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic;Demetri;Hematol Oncol Clin North Am,1995

3. Phase III trial of two investigational schedules of ifos-famide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study;Lorigan;J Clin Oncol,2007

4. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells;Druker;Nat Med,1996

5. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N Engl J Med,2003

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting 'Hallmarks of Cancer' In Sarcomas;Journal of Cancer;2024

2. Molecular mechanisms underpinning sarcomas and implications for current and future therapy;Signal Transduction and Targeted Therapy;2021-06-30

3. Nouveautés sur la caractérisation moléculaire des sarcomes des tissus mous;Bulletin du Cancer;2021-06

4. Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy;Lung Cancer;2020-10

5. Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG);Journal of Neuro-Oncology;2019-05-22